Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
Calvo
A
A
Department of Microbiology, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain.
Giménez
M J
MJ
Alou
L
L
Gómez-Lus
M L
ML
Aguilar
L
L
Prieto
J
J
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D018592:Cross-Over Studies; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D000077735:Gemifloxacin; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000008:administration & dosage / Q000494:pharmacology*; D015610:Serum Bactericidal Test; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000254:growth & development
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D002939:Ciprofloxacin; C080163:trovafloxacin; D000077735:Gemifloxacin